Clinical trials
BCLC Stage B Hepatocellular Carcinoma clinical trials
Below are recruiting bclc stage b hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 113 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07019844Recruiting
PSMA PET scan for liver cancer staging
This trial tests if a special PET scan (PSMA PET) can better stage liver cancer that has not been treated yet and is at a moderate to advanced stage (BCLC B or C). It may help guide treatment decisions.
West Los Angeles, CaliforniaAges 18 years+ - NCT07018518RecruitingPhase 1
Pin and immunotherapy combo for advanced liver cancer
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT06999707RecruitingPhase 2
Radiation plus immunotherapy for advanced liver cancer
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06999694RecruitingPhase 2
Proton radiation with immunotherapy for liver cancer
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06954467RecruitingPhase 2
Two immunotherapy drugs for advanced liver cancer
This study tests two new immunotherapy drugs (JS207 and JS007) as a first treatment for advanced liver cancer. It might be an option if you have not had any prior cancer medicine and your liver tumor is not blocking the main portal vein.
Hefei, AnhuiAges 18 years+ - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Phoenix, ArizonaAges 18 years+ - NCT06880523RecruitingPhase 2
Adding lenvatinib to immunotherapy for liver cancer
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Calgary, AlbertaAges 18 years+ - NCT05810402Recruiting
Testing immunotherapy for advanced liver cancer using blood tests
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
MontpellierAges 18 years+ - NCT06695026RecruitingPhase 1/Phase 2
Testing a new combination therapy for liver cancer
This trial tests a new drug, RZ-001, combined with valganciclovir, atezolizumab, and bevacizumab for people with hepatocellular carcinoma (a type of liver cancer). The goal is to see if this combination is safe and works better than current treatments.
BusanAges 18 years+ - NCT06632717RecruitingPhase 2
Chemo through liver artery with lipiodol for advanced liver cancer
This trial tests giving chemotherapy directly into the liver artery (HAIC) mixed with a special oil called lipiodol. It may help people with advanced liver cancer that cannot be treated with standard methods or who cannot tolerate them.
TaipeiAges 20 years+ - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT06339424RecruitingPhase 2
Atezolizumab and Bevacizumab with radiation for liver cancer that can't be removed
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06187961RecruitingPhase 2
Combination therapy for liver cancer that cannot be removed with surgery
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Wuhan, HubeiAges 18 years+ - NCT06172205RecruitingPhase 3
Two ways to give chemo plus immunotherapy for advanced liver cancer
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
Guangzhou, GuangdongAges 18–75 - NCT06133062RecruitingPhase 2
Study of atezolizumab, bevacizumab, and proton therapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
Taoyuan City, TaiwanAges 18 years+ - NCT05528952RecruitingPhase 2
Vaccine plus immunotherapy for unresectable liver cancer
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
BesançonAges 18 years+ - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05257590RecruitingPhase 2
CVM-1118 plus nivolumab for advanced liver cancer
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Kaohsiung CityAges 18 years+ - NCT05155189RecruitingPhase 1
Armored CAR-T treatment for advanced liver cancer
This Phase 1 trial tests the safety and early signs of effectiveness of an “armored” CAR-T cell therapy (C-CAR031) for advanced hepatocellular carcinoma (liver cancer). It may help by teaching the body’s immune cells to better recognize and attack the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70 - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT07408804Recruiting
Lenvatinib alone vs. with chemoembolization for liver cancer
This trial compares the combination of two treatments—chemoembolization (TACE) and lenvatinib—against lenvatinib alone for people with liver cancer that cannot be removed by surgery. It aims to see if the combination works better.
DhakaAges 18–75 - NCT07351669Recruiting
Spectral CT to check TACE response in liver cancer
This study uses a special type of CT scan (spectral CT) to see how well liver cancer has responded to a previous TACE treatment. If you've already had TACE for your liver cancer, this scan may help your doctors decide on the next steps, such as surgery or another procedure.
NanjingAges 18–75
Hear when a new BCLC Stage B Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bclc stage b hepatocellular carcinoma?
- Yes. Clin2 currently lists 113 recruiting bclc stage b hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bclc stage b hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bclc stage b hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- BCLC Stage C Hepatocellular Carcinoma
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Hepatocellular Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.